Elmsford

Researchers are evaluating a non-ablative 1470 nm laser treatment for people with androgenetic alopecia and scarring alopecia, types of hair loss confirmed by biopsy. This pilot study at a single center includes up to 10 participants divided into two groups of five for each type of alopecia. The goal is to explore the safety and effects of this laser that has FDA clearance for dermatologic use but is being tested off-label for hair loss treatment. Participants receive up to three treatments with the 1470 nm non-ablative HALO laser, which creates tiny controlled injuries in the scalp to improve healing and delivery of topical treatments. Before each session, topical anesthesia and antiseptic cleaning are applied, followed by laser treatment lasting about 10 to 15 minutes. Post-treatment care includes applying a steroid cream. Treatments target multiple scalp areas, and two groups are studied separately for androgenetic and scarring alopecia. During follow-up visits at months 6, 9, 12, and 15, researchers will assess hair loss and hair density using photos and the Canfield HairMetrix device. Participants complete questionnaires about pain and hair growth, and any side effects are monitored. Outcomes include photographic evaluations and hair counts compared to baseline. Participants must maintain their usual hair loss treatments without changes during the study and comply with all visits and protocols.

Researchers are evaluating the effectiveness and safety of a hybrid non-ablative/ablative laser called the Sciton Halo for treating acne scars in people with skin of color, focusing especially on those with Fitzpatrick IV and V skin types. Acne scarring, a common complication of acne caused by skin damage during healing, can negatively affect quality of life and mental health. Current treatments face challenges, particularly for atrophic scars, and this study explores a newer laser technology that may reduce side effects like hyperpigmentation. The study involves using the Sciton Halo hybrid fractional laser, which combines two wavelengths targeting both the skin's surface and deeper layers. This approach aims to stimulate collagen production and improve scar appearance while minimizing downtime and adverse effects. Participants receive this laser treatment following a specific protocol, with no other cosmetic procedures allowed in the treated areas during the study period. Participants will be monitored over about eight months to assess changes in acne scar severity, patient satisfaction, and quality of life related to dermatology. Assessments occur at baseline, and at 3, 5, and 8 months after treatment, including patient surveys and clinical evaluations. The study also tracks safety and tolerability throughout, requiring participants to follow the treatment and follow-up schedules carefully.

Researchers are evaluating the effectiveness of a non-ablative 1470 nm laser to treat scarring alopecia in adults. This study also aims to understand the molecular pathways involved by analyzing gene expression in hair follicles before and after laser treatment. The trial involves participants with biopsy-proven or clinically diagnosed scarring alopecia who have a stable hair loss treatment regimen. Participants will receive three laser treatments spaced one month apart, followed by five follow-up visits over a 15-month period. The laser treatment uses the Sciton HALOae device, which creates controlled micro-channels in the skin to improve treatment tolerance and efficiency. Each session lasts about 10 to 15 minutes, with topical anesthetic applied beforehand and standard post-treatment care. During the study, hair follicle samples will be collected by plucking 10 hairs before treatment and one month after completing treatment to analyze gene expression related to inflammation and fibrosis. Participants will complete questionnaires and keep diaries of any side effects. Researchers will assess outcomes like hair density, hair counts, and aesthetic improvement through clinical evaluations and specialized devices over the 15-month follow-up period.